12:00 AM
 | 
Apr 01, 2013
 |  BC Week In Review  |  Company News  |  Deals

Galapagos, Eli Lilly deal

Galapagos disclosed in an R&D update that it terminated a 2007 deal with Eli Lilly to discover compounds against 12 Galapagos targets to treat osteoporosis. Galapagos...

Read the full 109 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >